Spots Global Cancer Trial Database for CML Treated With Bosutinib After Relapse
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CML Treated With Bosutinib After Relapse
Official Title: Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment
Study ID: NCT02445742
Conditions
Interventions
Study Description
Brief Summary: Prospective, open label, multicenter, phase II study evaluating correlation of SNPs with efficacy and toxicity in patients treated with Bosutinib. A total of 50 patients with previously treated Ph+ chronic phase CML will be included in the study
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
C. H. U. de Gran Canaria Dr. Negrín, Gran Canaria, , Spain
C. H. Gregorio Marañón, Madrid, , Spain
C. U. La Paz - H. U. La Paz, Madrid, , Spain
H. Ramón y Cajal, Madrid, , Spain
H. U. de la Princesa, Madrid, , Spain
H. U. Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
C. H. Regional de Málaga , H. General, Málaga, , Spain
H. U. Son Espases, Palma de Mallorca, , Spain
C. Asistencial U. de Salamanca, Salamanca, , Spain
C. H. U. de Santiago, Santiago de Compostela, , Spain
H. Virgen de la Salud, Toledo, , Spain
Clínica Quirón Zaragoza S.A., Zaragoza, , Spain
Contact Details
Name: Luis Felipe Casado, Dr
Affiliation: PETHEMA Foundation
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
